Evidence map›Paper›PMID 42621266›Full record

ArticleiScience2026

L-asparaginase reversibly suppresses CD40-mediated B cell activation and antigen-presenting function by metabolic restriction.

Amar Hadzic, María Alejandra García-Márquez, Pol Bannasch, Nina Haindl, Katharina Frey, Martin Kirmaier, Maximilian A Funk, Anneli Tischmacher, Jingke Tu, Adriano Carboniero and 9 more

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Amar HadzicCancer and Immunometabolism Research Group, Gene Center LMU, Ludwig-Maximilians-Universität München, Munich, Germany.
María Alejandra García-MárquezCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Pol BannaschCancer and Immunometabolism Research Group, Gene Center LMU, Ludwig-Maximilians-Universität München, Munich, Germany.
Nina HaindlCancer and Immunometabolism Research Group, Gene Center LMU, Ludwig-Maximilians-Universität München, Munich, Germany.
Katharina FreyCancer and Immunometabolism Research Group, Gene Center LMU, Ludwig-Maximilians-Universität München, Munich, Germany.
Martin KirmaierCancer and Immunometabolism Research Group, Gene Center LMU, Ludwig-Maximilians-Universität München, Munich, Germany.
Maximilian A FunkCancer and Immunometabolism Research Group, Gene Center LMU, Ludwig-Maximilians-Universität München, Munich, Germany.
Anneli TischmacherCancer and Immunometabolism Research Group, Gene Center LMU, Ludwig-Maximilians-Universität München, Munich, Germany.
Jingke TuCancer and Immunometabolism Research Group, Gene Center LMU, Ludwig-Maximilians-Universität München, Munich, Germany.
Adriano CarbonieroCancer and Immunometabolism Research Group, Gene Center LMU, Ludwig-Maximilians-Universität München, Munich, Germany.
Ludovica VonaCancer and Immunometabolism Research Group, Gene Center LMU, Ludwig-Maximilians-Universität München, Munich, Germany.
Sabine OganesianCancer and Immunometabolism Research Group, Gene Center LMU, Ludwig-Maximilians-Universität München, Munich, Germany.
Lena MuschikCancer and Immunometabolism Research Group, Gene Center LMU, Ludwig-Maximilians-Universität München, Munich, Germany.
Hans SchlößerCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Martin VaethWürzburg Institute of Systems Immunology, Max Planck Research Group, Julius-Maximilians University of Würzburg, Würzburg, Germany.
Werner SchmitzDepartment of Biochemistry and Molecular Biology, Theodor Boveri Institute, Biocenter, Julius-Maximilians University of Würzburg, Würzburg, Germany.
Michael von Bergwelt-BaildonDepartment of Medicine III, LMU University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
David M Cordas Dos SantosCancer and Immunometabolism Research Group, Gene Center LMU, Ludwig-Maximilians-Universität München, Munich, Germany.
Sebastian TheurichCancer and Immunometabolism Research Group, Gene Center LMU, Ludwig-Maximilians-Universität München, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic reprogramming and nutrient uptake are essential for immune cell activation and adaptation. While asparagine is normally a non-essential amino acid, extracellular depletion by L-asparaginase (ASNase) is widely used to treat acute lymphoblastic leukemia and lymphoma. However, its effects on non-malignant B cells remain poorly understood. Using a model of CD40-mediated human B cell activation, we investigated the impact of ASNase on primary human B cells. Even at low, clinically sub-therapeutic concentrations, ASNase induced profound metabolic alterations, reducing glycolytic and mitochondrial respiratory capacity. This was accompanied by impaired proliferation and cluster formation without increasing cell death. Instead, ASNase suppressed B cell activation and antigen-presenting cell (APC) function while promoting the emergence of regulatory B cell phenotypes and immunosuppressive cytokine expression in a subset of cells. Supplementation with asparagine or glutamine restored APC function and proliferation, with glutamine showing slightly greater efficacy. These findings suggest that ASNase reversibly suppresses pro-inflammatory B cell functions through extensive metabolic reprogramming and may warrant evaluation as a potential immunosuppressive agent.

Indexed as

Antigen-presentationAsparaginaseB cellsB regulatory cellsimmunomodulation

Identifiers

PMID42621266
PMCPMC13487005

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.